CP316311 is a potent and selective CRF1 receptor antagonist used to fully antagonize CRF-stimulated adenylate cyclase activity in rat cortex and human CRF1 receptors endogenously expressed in IMR32 cells; it inhibits 125I-oCRF binding in rats, significantly attenuates activation of the hypothalamic–pituitary–adrenal (HPA) axis, and blocks the effects of both exogenous and endogenous CRF in the central nervous system (CNS) and in rat brain models.